| Chaperone-assisted E3 ligase CHIP: A double agent in cancer S Kumar, M Basu, MK Ghosh Genes & Diseases 9 (6), 1521-1555, 2022 | 19 | 2022 |
| Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients S Kumar, M Chatterjee, P Ghosh, KK Ganguly, M Basu, MK Ghosh Genes & Diseases 10 (4), 1318-1350, 2023 | 18 | 2023 |
| COVID‐19: Clinical status of vaccine development to date S Kumar, M Basu, P Ghosh, A Ansari, MK Ghosh British Journal of Clinical Pharmacology 89 (1), 114-149, 2023 | 18 | 2023 |
| COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery S Kumar, M Basu, P Ghosh, U Pal, MK Ghosh Genes & Diseases, 2023 | 6 | 2023 |
| COVID-19 and cancer: insights into their association and influence on genetic and epigenetic landscape MK Ghosh, S Kumar, KK Ganguly, P Ghosh, S Tabassum, B Basu, M Basu Epigenomics 15 (4), 227-248, 2023 | 3 | 2023 |
| PLGA-based dual-loaded nanoformulation of DIM and TMZ-An advanced clinical strategy for brain cancer treatment in a combinatorial approach S Sarkar, S Kumar, G Saha, M Basu, MK Ghosh bioRxiv, 2023.05. 04.539373, 2023 | | 2023 |
